Antihypertensive Effectiveness of Perindopril Arginine and Indapamide Single-Pill Combination According to Body Mass Index: Findings from the FORSAGE Study.
Blood pressure target
Body mass index
Indapamide
Obesity
Perindopril arginine
Quality of life
Single-pill combinations
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
10
10
2019
pubmed:
3
2
2020
medline:
3
2
2020
entrez:
3
2
2020
Statut:
ppublish
Résumé
Overweight and obesity are increasing worldwide and are associated with an increased risk for cardiovascular disease (CVD). The aim of this study was to examine the burden of CVD risk factors among normal weight, overweight, and obese subjects with hypertension, and to evaluate the effectiveness of switching to a single-pill combination (SPC) of perindopril arginine/indapamide for blood pressure (BP) control in overweight and obese subjects treated in routine clinical practice. FORSAGE was a 3-month, multicenter, observational, open-label study conducted in Russian patients with uncontrolled arterial hypertension under previous antihypertensive therapy. Subjects were switched to the full-dose perindopril arginine 10 mg/indapamide 2.5 mg SPC. BP was assessed at 2 weeks, 1 month, and 3 months, and serum creatinine and general health status at 3 months. The present post hoc analysis of the FORSAGE study results explored the effectiveness of perindopril arginine/indapamide SPC in patients with arterial hypertension with regard to baseline body mass index (BMI): normal (< 25 kg/m A total of 1969 patients were recruited, but BMI data were available for 1963 patients, two-thirds of whom were women. The distribution of BMI groups was as follows: < 25 kg/m In subjects with uncontrolled BP on existing antihypertensive therapy, switching to perindopril arginine 10 mg/indapamide 2.5 mg was associated with statistically significant decreases in BP and higher rates of target BP achievement in all BMI groups, including more than 70% of overweight and obese patients. ISRCTN ID, ISRCTN14315146 (retrospectively registered 18/11/2019).
Identifiants
pubmed: 32008207
doi: 10.1007/s40119-020-00162-x
pii: 10.1007/s40119-020-00162-x
pmc: PMC7237592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139-152Investigateurs
E A Sebko
(EA)
E E Popova
(EE)
M N Gaponova
(MN)
O S Doronina
(OS)
I V Dvornikova
(IV)
E D Oleynikova
(ED)
E V Slyusarenko
(EV)
A A Shepelenko
(AA)
N S Safonova
(NS)
N N Bliznyuk
(NN)
Z K Botasheva
(ZK)
N V Sukmanova
(NV)
E S Sergeeva
(ES)
A N Shinkarenko
(AN)
L P Shchepelyova
(LP)
E M Chuiko
(EM)
O E Kondratieva
(OE)
M S Fetiskina
(MS)
E I Kharitonova
(EI)
I S Agafonova
(IS)
N E Zhidkova
(NE)
L L Gridyaeva
(LL)
N R Kolosova
(NR)
D P Kuzmina
(DP)
A B Aleeva
(AB)
S F Merkulova
(SF)
M V Kitaeva
(MV)
A I Arkhipova
(AI)
N N Arkhipova
(NN)
T A Nikitina
(TA)
N B Putilina
(NB)
O A Oleynik
(OA)
T K Petukhova
(TK)
V Yu Grushichev
(VY)
N I Uchanina
(NI)
N A Stopyatyuk
(NA)
E Yu Fedorova
(EY)
G Ya Gerent
(GY)
L N Gulakova
(LN)
K V Buzmakova
(KV)
T I Anisimova
(TI)
E I Mangusheva
(EI)
M N Deryabina
(MN)
A L Blinova
(AL)
D V Ivanov
(DV)
E L Isaeva
(EL)
N V Medvedeva
(NV)
O A Khayrullina
(OA)
A N Khusnudinov
(AN)
K G Khusnudinova
(KG)
A I Karimov
(AI)
V R Karimov
(VR)
R S Sagitov
(RS)
I M Gainutdinov
(IM)
S A Vasilyeva
(SA)
Yu Yu Kapisova
(YY)
O Yu Fadeeva
(OY)
E R Nesterova
(ER)
A Sh Shagaeva
(AS)
V Kh Sirazieva
(VK)
E D Minagulova
(ED)
T N Odarenko
(TN)
A P Ivanova
(AP)
N P Karpova
(NP)
O V Mityagina
(OV)
M V Sadakova
(MV)
T D Kolpakova
(TD)
S S Kozlov
(SS)
A V Kholodova
(AV)
T A Lushkova
(TA)
M N Zlobina
(MN)
E A Korchemkina
(EA)
M A Dubovskikh
(MA)
E M Kupreeva
(EM)
M V Mikheenko
(MV)
O A Zadumina
(OA)
O A Ivanova
(OA)
E Yu Zhemartseva
(EY)
N V Dugina
(NV)
V G Ananenko
(VG)
N A Korobskaya
(NA)
A S Sokolenko Aksenova
(AS)
A A Sobolenko
(AA)
E N Zavgorodnyaya
(EN)
E V Shiyanova
(EV)
I A Bakhmetieva
(IA)
I F Krepetula
(IF)
S V Shineleva
(SV)
E E Tavrizyan
(EE)
E E Ivanitskaya
(EE)
V B Rybyakova
(VB)
T A Andriyasheva
(TA)
N Yu Golovanova
(NY)
S N Kurbanova
(SN)
V G Dorofeychik
(VG)
L D Stepanyuk
(LD)
Yu V Domracheva
(YV)
N B Vasilievna
(NB)
E E Griboleva
(EE)
V S Ratushnyak
(VS)
E M Tipsina
(EM)
G I Shchukina
(GI)
O B Savina
(OB)
E V Kondrashova
(EV)
O K Labenskaya
(OK)
A A Lyashenko
(AA)
T A Burova
(TA)
I E Apanovich
(IE)
N K Babashkina
(NK)
L G Prokhorova
(LG)
Yu V Starodubets
(YV)
T N Podlesnaya
(TN)
V N Shustov
(VN)
S V Gordeev
(SV)
N V Urinskaya
(NV)
R Kh Abdrashitov
(RK)
E M Tsybulnikova
(EM)
M V Khaibullin
(MV)
D Yu Dzhimbieva
(DY)
A V Pogonchikova
(AV)
G K Alaeva
(GK)
A V Prudnikova
(AV)
Yu N Cherepanov
(YN)
A V Nosurak
(AV)
S I Myagkova
(SI)
N I Pakhomova
(NI)
M M Adamyan
(MM)
S V Bogomolova
(SV)
E A Vinogradova
(EA)
S I Stakhanova
(SI)
E Yu Tikhonova
(EY)
V A Stakhanov
(VA)
A V Demidova
(AV)
O V Sahakyan
(OV)
T V Bykova
(TV)
I A Blinova
(IA)
I V Primasyuk
(IV)
A V Egorov
(AV)
A S Vozisov
(AS)
A A Ivanov
(AA)
T B Kontsevaya
(TB)
T M Mochalina
(TM)
N V Moskvicheva
(NV)
N E Tatarenko
(NE)
E A Semenova
(EA)
N N Nazarova
(NN)
V Balakina
(V)
K V Sahakova
(KV)
A V Aleksandrov
(AV)
A V Zaitsev
(AV)
E A Lagutina
(EA)
I Yu Khmelevskaya
(IY)
E Ch Beslaneeva
(EC)
R P Sidorova
(RP)
D V Cherdintseva
(DV)
M V Cherdintsev
(MV)
G A Pervusheva
(GA)
A S Gavrilova
(AS)
O G Vikhreva
(OG)
E S Khachikyan
(ES)
E N Bozhkova
(EN)
T V Tikhtiy
(TV)
R E Kapinos
(RE)
O V Rozova
(OV)
E A Guseva
(EA)
S A Peredernin
(SA)
E G Nikolaeva
(EG)
T A Nikolaeva
(TA)
O V Lebedeva
(OV)
I V Ayrapetova
(IV)
A M Rizaev
(AM)
E A Titova
(EA)
I V Marmurova
(IV)
Ya V Semko
(YV)
E I Chernushkina
(EI)
O V Mandzhieva
(OV)
N S Dmitrieva
(NS)
R Sh Zhugunisova
(RS)
O P Semenova
(OP)
L E Komissarova
(LE)
E V Illarionova
(EV)
E P Patrusheva
(EP)
L N Batmanova
(LN)
N P Davydova
(NP)
S B Markina
(SB)
Y I Khromenkova
(YI)
I S Skulova
(IS)
S A Bunaeva
(SA)
E A Kosolapova
(EA)
Yu V Bobkova
(YV)
O V Epifanova
(OV)
M A Podrezova
(MA)
N L Nikonova
(NL)
A A Timofeev
(AA)
E N Shatalova
(EN)
I V Mulin
(IV)
E I Ugolkova
(EI)
A P Sorochkina
(AP)
M V Zhogoleva
(MV)
G V Dyakova
(GV)
T N Maslikova
(TN)
N V Moskovkina
(NV)
T V Khromova
(TV)
I Yu Frantsuzova
(IY)
L V Zubareva
(LV)
A V Mamonova
(AV)
S V Samsonova
(SV)
T I Demchuk
(TI)
E A Vikhman
(EA)
A N Nikitina
(AN)
O S Sventsitskaya
(OS)
L P Gorbunova
(LP)
S G Shkulov
(SG)
N V Beletskaya
(NV)
N V Vazina
(NV)
T N Sevostyanova
(TN)
A G Trilinskaya
(AG)
G N Bolotskaya
(GN)
S N Merkitanova
(SN)
E N Andrianova
(EN)
N S Sadovskaya
(NS)
A V Polischuk
(AV)
A N Davletova
(AN)
M A Romanova
(MA)
A V Shapalina
(AV)
S A Gavrilova
(SA)
N A Ivanova
(NA)
E G Halimova
(EG)
A O Sharikhina
(AO)
N A Tokareva
(NA)
Yu V Stukan
(YV)
A E Efremova
(AE)
E P Novikova
(EP)
L L Zakaryan
(LL)
Yu S Vasilieva
(YS)
N N Ponomarenko
(NN)
S Kh Kuchinova
(SK)
T Yu Novoselova
(TY)
E A Turusheva
(EA)
E V Saenko
(EV)
E D Kromm
(ED)
Yu V Ivzhenko
(YV)
G G Ryabchuk
(GG)
T M Sabakar
(TM)
N G Reshetnikova
(NG)
L V Fedorova
(LV)
O A Novoselova
(OA)
T V Volodchenko
(TV)
T N Pashkovskaya
(TN)
N A Adamova
(NA)
R A Davletshina
(RA)
E V Vasilieva
(EV)
L N Shitik
(LN)
M V Marenich
(MV)
S A Murotova
(SA)
E M Fedorova
(EM)
S G Suvorova
(SG)
A A Kvashnina
(AA)
L A Lonkina
(LA)
S A Nikitenko
(SA)
A V Morozova
(AV)
G P Donskikh
(GP)
E V Asessorova
(EV)
A A Zakharova
(AA)
A N Vetrova
(AN)
E V Fedotova
(EV)
M R Faizulina
(MR)
I Yu Minaevskaya
(IY)
T N Mitroshina
(TN)
M V Strebkova
(MV)
M L Ovsyannikova
(ML)
Yu S Zhigacheva
(YS)
V K Larina
(VK)
S P Serikova
(SP)
G S Shirganova
(GS)
E V Usanova
(EV)
O A Musailova
(OA)
L N Pozdina
(LN)
N V Kriulina
(NV)
Ya S Drondina
(YS)
V A Pikuleva
(VA)
V V Goncharova
(VV)
S F Lukina
(SF)
V I Zvereva
(VI)
V V Ershova
(VV)
S D Tyabut Gudkova
(SD)
A Yu Baslakovskaya
(AY)
A E Petrina
(AE)
L V Solovyeva
(LV)
O G Edigarova
(OG)
O V Babich
(OV)
Y V Shtefa
(YV)
A B Zograbyan
(AB)
O Yu Ivanova
(OY)
V A Luka
(VA)
S N Lebed
(SN)
E I Khadzhieva
(EI)
I A Kulakova
(IA)
T P Tolstokoneva
(TP)
L V Dobosotskaya
(LV)
E M Dranishnikova
(EM)
N G Bunina
(NG)
N N Panchenko
(NN)
N Yu Varnovskaya
(NY)
N E Shulgina
(NE)
T N Boboshko
(TN)
E A Pyshyeva
(EA)
G I Gaystruk
(GI)
M G Sergeeva
(MG)
I V Fartushnova
(IV)
T A Traba
(TA)
V I Gordon
(VI)
M V Kolesnikova
(MV)
G G Polyakova
(GG)
M A Goryachkina
(MA)
O V Goloshchapova
(OV)
O L Novichkova
(OL)
N V Sleptsova
(NV)
Yu V Raldugina
(YV)
O P Lyubimova
(OP)
I V Amirova
(IV)
I Z Chkhachkhalia
(IZ)
E V Koroleva
(EV)
E A Alieva
(EA)
N P Kurilova
(NP)
E S Bogdanova
(ES)
P Yu Ketsko
(PY)
A L Malenev
(AL)
N I Fomicheva
(NI)
M P Zaytseva
(MP)
N V Furtova
(NV)
L A Biryukova
(LA)
E G Aleshugina
(EG)
E V Ushakova
(EV)
N P Eliseeva
(NP)
O G Kiryanova
(OG)
I S Ermilova
(IS)
V A Stanovaya
(VA)
M V Petrova
(MV)
L P Kulina
(LP)
N V Yekimova
(NV)
I M Tikotina
(IM)
N T Arteeva
(NT)
E A Lapina
(EA)
O Yu Lushanina
(OY)
T A Volynskaya
(TA)
Yu M Bliznyukova
(YM)
A F Vikhrova
(AF)
E Yu Loseva
(EY)
M I Maltseva
(MI)
M V Kozlova
(MV)
N V Ivanova
(NV)
E G Pavlova
(EG)
Yu N Sozi
(YN)
O M Khorobrova
(OM)
L I Grekova
(LI)
A R Matyushina
(AR)
I N Gomonova
(IN)
Yu D Malyshev
(YD)
G V Ivantsova
(GV)
V A Verkhovskaya
(VA)
E A Nosova
(EA)
S O Zikun
(SO)
L V Sokhen
(LV)
E L Vologdina
(EL)
A V Shelepov
(AV)
E A Atzpol
(EA)
G R Timaeva
(GR)
I N Maksimenko
(IN)
K S Shcherbak
(KS)
O V Pobegay
(OV)
N V Pleskanovskaya
(NV)
Yu V Chuchin
(YV)
A I Nesterov
(AI)
I D Skripka
(ID)
I A Nevolina
(IA)
L V Li
(LV)
N V Ryabova
(NV)
E N Perevoznikova
(EN)
N N Morozova
(NN)
E V Volkova
(EV)
I V Vlasova
(IV)
E V Reznikova
(EV)
N S Tregubenko
(NS)
N S Tregubova
(NS)
M A Goncharova
(MA)
A V Kotova
(AV)
E R Munipova
(ER)
K A Gasparyan
(KA)
T F Sherstobitova
(TF)
L I Zagrutdinova
(LI)
Yu K Gilmanova
(YK)
I R Ismagilova
(IR)
Yu V Mustaeva
(YV)
Yu A Doynikova
(YA)
A F Kharasova
(AF)
A S Koshmanova
(AS)
T N Ponomareva
(TN)
L V Zahezina
(LV)
N V Smolnikova
(NV)
N V Golubeva
(NV)
N V Mingaleva
(NV)
E V Lapchenkova
(EV)
Yu V Kukharets
(YV)
A A Lozikova
(AA)
N S Ushakova
(NS)
L M Katyrova
(LM)
M A Bezmenova
(MA)
M V Chikova
(MV)
M P Demidova
(MP)
L N Lebedeva
(LN)
I A Merkulyeva
(IA)
A A Voronik
(AA)
O P Cherenkova
(OP)
N A Tereneva
(NA)
V M Kapralova
(VM)
B M Romanycheva
(BM)
S A Sitnikova
(SA)
I A Lenivkova
(IA)
E V Khazanova
(EV)
M V Palshina
(MV)
M V Sheveleva
(MV)
T A Shalycheva
(TA)
L V Kirsanova
(LV)
T A Marakhonova
(TA)
E A Rafikova
(EA)
M V Smirnova
(MV)
M G Dobrolyubova
(MG)
O M Rogozina
(OM)
Références
Li YT, Wang HH, Liu KQ, Lee GK, Chan WM, Griffiths SM, et al. Medication adherence and blood pressure control among hypertensive patients with coexisting long-term conditions in primary care settings: a cross-sectional analysis. Medicine (Baltimore). 2016;95:e3572.
doi: 10.1097/MD.0000000000003572
La Sierra A, Oliveras A, Armario P, Lucas S. Control de la presión arterial en pacientes en tratamiento con terapia combinada. Med Clin (Barc). 2015;144:145–50.
doi: 10.1016/j.medcli.2013.09.033
Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, et al. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One. 2012;7:e52229.
doi: 10.1371/journal.pone.0052229
Chopra I, Kamal KM, Candrilli SD, Kanyongo G. Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgrad Med. 2014;126:66–77.
doi: 10.3810/pgm.2014.01.2726
Schmieder RE, Gitt AK, Koch C, Bramlage P, Ouarrak T, Tschöpe D. Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. BMC Endocr Disord. 2015;15:23.
doi: 10.1186/s12902-015-0020-7
Reibis RK, Huber M, Karoff M, Kamke W, Kreutz R, Wegscheider K, et al. Target organ damage and control of cardiovascular risk factors in hypertensive patients. Evidence from the multicenter ESTher registry. Herz. 2015;40(Suppl 2):209–16.
doi: 10.1007/s00059-014-4189-8
Friedberg JP, Rodriguez MA, Watsula ME, Lin I, Wylie-Rosett J, Allegrante JP, et al. Effectiveness of a tailored behavioral intervention to improve hypertension control: primary outcomes of a randomized controlled trial. Hypertension. 2015;65:440–6.
doi: 10.1161/HYPERTENSIONAHA.114.03483
Glezer MG, Deev AD. How to increase the effectiveness of antihypertensive therapy in clinical practice: results of the Russian observational program FORSAZH. Kardiologiia. 2016;56:18–24.
doi: 10.18565/cardio.2016.1.18-24
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
doi: 10.1016/j.metabol.2018.09.005
Zhernakova YV, Zheleznova EA, Chazova IE, Oshchepkova EV, Dolgusheva YA, Yarovaya EB, et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study—ESSE-RF. Ter Arkh. 2018;90(10):14–22.
pubmed: 30701790
Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280–7.
doi: 10.1001/jamacardio.2018.0022
Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens. 2008;26:2064–70.
doi: 10.1097/HJH.0b013e32830c45c3
Zidek W, Naditch-Brûlé L, Perlini S, Farsang C, Kjeldsen SE. Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol. 2009;8:51.
doi: 10.1186/1475-2840-8-51
Astashkin EI, Glezer MG. Obesity and arterial hypertension [Russian]. Probl Women Health. 2008;4(3):23–33.
Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Salasyuk AS, Smirnova VO, et al. Optimization of control of blood pressure, metabolic disorders and target organ protection with fixed perindopril and indapamide combination in treated patients with arterial hypertension. Kardiologiia. 2017;57:5–11.
pubmed: 28290783
Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041–6.
doi: 10.1161/HYPERTENSIONAHA.114.05021
Wang S, Li J, Zhou X, Liu K, Zhang X, Meng Q, et al. Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. J Hum Hypertens. 2017;31:848–54.
doi: 10.1038/jhh.2017.51
DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015;11:203–17.
doi: 10.2217/fca.14.83
Wan C, Su H, Zhang C. Role of NADPH oxidase in metabolic disease-related renal injury: an update. Oxid Med Cell Longev. 2016;2016:7813072.
doi: 10.1155/2016/7813072
Zanoli L, Lentini P, Briet M, Castellino P, House AA, London GM, Malatino L, McCullough PA, Mikhailidis DP, Boutouyrie P. Arterial stiffness in the heart disease of CKD. J Am Soc Nephrol. 2019;30(6):918–28.
doi: 10.1681/ASN.2019020117
Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.
doi: 10.1046/j.1523-1755.2001.0590041498.x
Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. Blood Purif. 2017;43:346–54.
doi: 10.1159/000458481
Ionescu DD. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig. 2009;29:767–76.
doi: 10.2165/11319700-000000000-00000
Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril–indapamide combination as first-line treatment of hypertension. Clin Ther. 2004;26(2):257–70.
doi: 10.1016/S0149-2918(04)90024-0
Mourad JJ, Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients. Curr Med Res Opin. 2009;25(9):2271–80. https://doi.org/10.1185/03007990903186787 .
doi: 10.1185/03007990903186787
pubmed: 19627177
Netchessova TA, Shepelkevich AP, Gorbat TV, NIKA Study Group. Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes. High Blood Press Cardiovasc Prev. 2014;21(1):63–9.
doi: 10.1007/s40292-013-0036-x
Carnagarin R, Matthews V, Gregory C, Schlaich MP. Pharmacotherapeutic strategies for treating hypertension in patients with obesity. Expert Opin Pharmacother. 2018;19:643–51.
doi: 10.1080/14656566.2018.1458092
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
doi: 10.1016/S0140-6736(05)67185-1
Wenzel UO, Benndorf R, Lange S. Treatment of arterial hypertension in obese patients. Semin Nephrol. 2013;33:66–74.
doi: 10.1016/j.semnephrol.2012.12.009
Nedogoda SV, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013;33:553–61.
doi: 10.1007/s40261-013-0094-9
Ogilvie RI, Anand S, Roy P, Souza S. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors. Clin Drug Investig. 2008;28:673–86.
doi: 10.2165/00044011-200828110-00001
Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol. 1998;32(4):616–20.
doi: 10.1097/00005344-199810000-00014
Semenkin AA, Zhenatov AB, Zhivilova LA, Nechaeva GI, Pritykina TV, Chindareva OI, et al. Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide. Kardiologiia. 2014;54(11):25–9.
doi: 10.18565/cardio.2014.11.25-29